Connect Biopharma Holdings Limited
NASDAQ:CNTB · NASDAQ Global Market
-$0.09 today
Vol 0.20M · Avg 0.30M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $38.3M |
| Short-term Investments | $6.0M |
| Receivables | $161.0K |
| Other Current | $6.4M |
| Total Current Assets | $50.9M |
| PP&E (Net) | $4.5M |
| Intangible Assets | $45.0K |
| Other Non-current | $646.0K |
| Total Non-current Assets | $5.1M |
| Total Assets | $56.1M |
Analysis
Selected assets total $56.1M for Latest. The largest visible component is Cash & Equivalents at $38.3M, about 68.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.3M -51.0% | $78.2M -26.0% | $105.7M +33.7% | $79.0M -70.5% | $267.7M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $6.0M -61.2% | $15.5M +22.4% | $12.6M -82.8% | $73.4M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $161.0K -84.7% | $1.1M +199.4% | $351.0K +51.3% | $232.0K -96.9% | $7.4M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $29.0K -93.1% | $419.0K +675.9% | $54.0K | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $50.9M -47.5% | $97.0M -20.9% | $122.6M -21.3% | $155.8M -43.4% | $275.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $4.5M +5.1% | $4.2M -10.5% | $4.7M -11.9% | $5.4M -43.0% | $9.4M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $45.0K -15.1% | $53.0K -14.5% | $62.0K -98.0% | $3.2M -10.5% | $3.5M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 -100.0% | $9.4M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $646.0K +1857.6% | $33.0K +37.5% | $24.0K -90.5% | $252.0K -91.5% | $3.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $5.1M +19.0% | $4.3M -10.3% | $4.8M -73.6% | $18.2M +14.5% | $15.9M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $56.1M -44.6% | $101.3M -20.5% | $127.4M -26.8% | $174.0M -40.2% | $291.1M | $13.3B | $11.9B | $10.6B |
| Account Payables | $2.0M +474.3% | $342.0K -84.5% | $2.2M -81.5% | $11.9M -6.3% | $12.7M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $167.0K +1.8% | $164.0K -98.8% | $13.3M | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.9M -12.8% | $3.3M +62.9% | $2.1M | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $13.6M +60.9% | $8.5M -66.5% | $25.3M +61.9% | $15.6M -13.1% | $18.0M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 -100.0% | $405.0K -37.9% | $652.0K -16.8% | $784.0K | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $114.0K -82.0% | $632.0K | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $482.0K -26.5% | $656.0K +12.1% | $585.0K -34.8% | $897.0K +10.7% | $810.0K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $14.1M +54.6% | $9.1M -64.8% | $25.9M +56.6% | $16.5M -12.1% | $18.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $10.0K +0.0% | $10.0K +0.0% | $10.0K +0.0% | $10.0K +0.0% | $10.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$400.8M -16.1% | -$345.4M -4.7% | -$329.7M +31.3% | -$479.8M -32.6% | -$361.8M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.2M +28.5% | -$1.7M -65.3% | -$1.0M +86.8% | -$7.6M -89.4% | -$4.0M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 -100.0% | $16.5M +72.2% | $9.6M | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $42.0M -54.5% | $92.2M -9.2% | $101.5M -35.6% | $157.5M -42.2% | $272.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $690.0K +287.6% | $178.0K -61.7% | $465.0K +7.9% | $431.0K +244.8% | $125.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$37.7M +51.8% | -$78.1M +25.8% | -$105.2M -33.9% | -$78.6M +70.6% | -$267.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
Sutro Biopharma, Inc.
NASDAQ:STRO
$281.94M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$234.93M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.94M
InflaRx N.V.
NASDAQ:IFRX
$130.47M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
ImageneBio Inc
NASDAQ:IMA
$68.52M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.81M
Metagenomi, Inc. Common Stock
MGX
$45.93M
Quince Therapeutics, Inc.
QNCX
$5.03M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does CNTB have?
Connect Biopharma Holdings Limited (CNTB) reported $38.34M in cash and equivalents in fiscal 2025.
How much debt does CNTB carry?
Connect Biopharma Holdings Limited (CNTB) reported $690,000.00 of total debt, with net debt of -$37,655,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.